New hope for asthma and polyp sufferers? mepolizumab under the microscope

NCT ID NCT04823585

Completed Disease control Sponsor: Helsinki University Central Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether the drug mepolizumab can improve symptoms in people with a specific combination of asthma, nasal polyps, and sensitivity to aspirin or similar painkillers. 95 adults received either mepolizumab or a placebo injection every month for 16 weeks. Researchers measured changes in nasal symptoms and polyp size to see if the drug works better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mepolizumab
What this could lead to: If successful, mepolizumab could offer a more effective way to control severe asthma and nasal polyp symptoms, reducing the need for extra medications.
What could go wrong: This is a small, completed Phase 4 study with 95 participants, so results may not apply to everyone. As with any biologic, there is a risk of side effects like allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aspirin-induced respiratory disease asthma Asthma, Aspirin-Induced asthma, nasal polyps, and aspirin intolerance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA, ASPIRIN-INDUCED CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Contacts and locations

Locations

Helsinki University Hospital

Helsinki, 00029, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.